scholarly journals Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis

2018 ◽  
Vol 2018 ◽  
pp. 1-19 ◽  
Author(s):  
Kyeong-Ah Kwak ◽  
Hyun-Jae Cho ◽  
Jin-Young Yang ◽  
Young-Seok Park
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Mechanisms Of Action ◽  
Clinical Applications ◽  
Hepatic Regeneration ◽  
Future Perspectives ◽  
Cell Type ◽  
Cell Based Therapy ◽  
Preclinical And Clinical Studies ◽  
Different Origins

Liver cirrhosis is a major cause of mortality and a common end of various progressive liver diseases. Since the effective treatment is currently limited to liver transplantation, stem cell-based therapy as an alternative has attracted interest due to promising results from preclinical and clinical studies. However, there is still much to be understood regarding the precise mechanisms of action. A number of stem cells from different origins have been employed for hepatic regeneration with different degrees of success. The present review presents a synopsis of stem cell research for the treatment of patients with liver cirrhosis according to the stem cell type. Clinical trials to date are summarized briefly. Finally, issues to be resolved and future perspectives are discussed with regard to clinical applications.

Current Perspectives Regarding Stem Cell-based Therapy for Ischemic Stroke

2018 ◽  
Vol 24 (28) ◽  
pp. 3332-3340 ◽  
Author(s):  
Kyeong-Ah Kwak ◽  
Ho-Beom Kwon ◽  
Joo Won Lee ◽  
Young-Seok Park
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Ischemic Stroke ◽  
Time Window ◽  
Experimental Studies ◽  
Cell Type ◽  
Stroke Treatment ◽  
Cell Based Therapy ◽  
Regenerative Approach ◽  
Therapeutic Time Window

Stroke is a leading cause of death and disability worldwide. Conventional treatment has a limitation of very narrow therapeutic time window and its devastating nature necessitate a novel regenerative approach. Transplanted stem cells resulted in functional recovery through multiple mechanisms including neuroprotection, neurogenesis, angiogenesis, immunomodulation, and anti-inflammatory effects. Despite the promising features shown in experimental studies, results from clinical trials are inconclusive from the perspective of efficacy. The present review presents a synopsis of stem cell research on ischemic stroke treatment according to cell type. Clinical trials to the present are briefly summarized. Finally, the hurdles and issues to be solved are discussed for clinical application.

scholarly journals Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications

2021 ◽  
Vol 13 (5) ◽  
pp. 386-415
Author(s):  
Xi-Min Hu ◽  
Qi Zhang ◽  
Rui-Xin Zhou ◽  
Yan-Lin Wu ◽  
Zhi-Xin Li ◽  
...  
Keyword(s):  
Cell Death ◽  
Stem Cell ◽  
Programmed Cell Death ◽  
Clinical Applications ◽  
Cell Based Therapy

scholarly journals Perspectives of Stem Cell–Based Therapy for Age-Related Retinal Degenerative Diseases

2017 ◽  
Vol 26 (9) ◽  
pp. 1538-1541 ◽  
Author(s):  
Vladimir Holan ◽  
Barbora Hermankova ◽  
Jan Kossl
Keyword(s):  
Stem Cell ◽  
Treatment Protocol ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Degenerative Diseases ◽  
Cell Type ◽  
Retinal Cells ◽  
Cell Based Therapy ◽  
Age Related ◽  
Retinal Degenerative Diseases

Retinal degenerative diseases, which include age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and glaucoma, mostly affect the elderly population and are the most common cause of decreased quality of vision or even blindness. So far, there is no satisfactory treatment protocol to prevent, stop, or cure these disorders. A great hope and promise for patients suffering from retinal diseases is represented by stem cell–based therapy that could replace diseased or missing retinal cells and support regeneration. In this respect, mesenchymal stem cells (MSCs) that can be obtained from the particular patient and used as autologous cells have turned out to be a promising stem cell type for treatment. Here we show that MSCs can differentiate into cells expressing markers of retinal cells, inhibit production of pro-inflammatory cytokines by retinal tissue, and produce a number of growth and neuroprotective factors for retinal regeneration. All of these properties make MSCs a prospective cell type for cell-based therapy of age-related retinal degenerative diseases.

scholarly journals Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications

2013 ◽  
Vol 238 (3) ◽  
pp. 294-300 ◽  
Author(s):  
Yaoliang L Tang ◽  
Yingjie J Wang ◽  
Lijuan J Chen ◽  
Yaohua H Pan ◽  
Lan Zhang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Stem Cell ◽  
Clinical Applications ◽  
Cell Based Therapy

scholarly journals Commercial Production of Autologous Stem Cells and Their Therapeutic Potential for Liver Cirrhosis

2017 ◽  
Vol 26 (3) ◽  
pp. 449-460 ◽  
Author(s):  
Yi-Chun Lin ◽  
Horng-Jyh Harn ◽  
Po-Cheng Lin ◽  
Ming-Hsi Chuang ◽  
Chun-Hung Chen ◽  
...  
Keyword(s):  
Stem Cells ◽  
Liver Cirrhosis ◽  
Stem Cell ◽  
Therapeutic Potential ◽  
Dose Range ◽  
Tumor Development ◽  
Commercial Production ◽  
Production Program ◽  
Cell Based Therapy ◽  
Promising Source

Human adipose-derived stem cells (hADSCs) are a promising source of autologous stem cells for personalized cell-based therapies. Culture expansion of ADSCs provides an attractive opportunity for liver cirrhosis patients. However, safety and stability issues can pose big challenges for personalized autologous stem cell products. In the present study, we addressed whether the commercial production program could provide a consistent product for liver cirrhosis therapy. We collected adipose tissue from three human donors by lipoaspirate and isolated ADSCs, which were expanded in culture to reach 1 × 10 8 cells (an approximately 1,000-fold expansion) within four passages. We then examined their morphology, chromosome stability, surface markers, and differentiation ability after culture. Next, we explored their therapeutic potential using a rat model of thioacetamide-induced liver cirrhosis. Culture-expanded ADSCs were injected intrahepatically, and their biodistribution was tracked by immunohistochemistry using an antibody against human mitochondria. Finally, we tested for tumor development by subcutaneously injecting a 100-fold dose range of cultured ADSCs into immunocompromised mice. Taken together, we find that culture expansion of autologous ADSCs is a potentially suitable stem cell product for personalized cell-based therapy for patients with liver cirrhosis.

scholarly journals Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives

2017 ◽  
Vol 4 (2) ◽  
Author(s):  
Gounder Sellamuthu Subbanna ◽  
Kodiappan Radha ◽  
Chan Soon Choy ◽  
Veerakumarasivam Abhi ◽  
Subramani Baskar
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Adult Stem Cell ◽  
Future Perspectives ◽  
Current Practices

scholarly journals Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives

2019 ◽  
Vol 109 ◽  
pp. 2318-2326 ◽  
Author(s):  
C. Randall Harrell ◽  
Bojana Simovic Markovic ◽  
Crissy Fellabaum ◽  
Aleksandar Arsenijevic ◽  
Vladislav Volarevic
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Current Knowledge ◽  
Future Perspectives ◽  
Cell Based Therapy
Sign in / Sign up

Export Citation Format

Share Document